A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation

NCT04582409 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated due to business decision

Conditions

Atrial Fibrillation

Interventions

DRUG: HSY244
OTHER: Placebo

Sponsor

Novartis Pharmaceuticals